


(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/509,972
Filing Date	October 1, 2004
First Named Inventor	Xiong et al.
Group Art Unit	To be Assigned
Examiner Name	To be Assigned
Attorney Docket Number	21111YP



Sheet 1 of 2

[illegible][illegible]

06/06/2007

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 10/509,972
 Filing Date October 1, 2004
 First Named Inventor Xiong et al.
 Group Art Unit To be Assigned
 Examiner Name To be Assigned
 Attorney Docket Number 21111YP



Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Examiner Initials*	Cite No.	
/S.C./	6.	J. M. Clements et al., "Antibacterial Activities and Characterization of Novel Inhibitors of LpxC", 2002, pp. 1793-1799, Vol. 46, No. 6, Antimicrobial Agents and Chemotherapy.
	7.	D. P. Becker et al., "Alpha-Amino-Beta-Sulphone Hydroxamates as Potent MMP-13 Inhibitors that Spare MMP-1", pp. 2719-2722, Vol. 11, Bioorganic & Medicinal Chemistry Letters.
	8.	T. C. Dixon et al., "Anthrax", 1999, pp. 815-820, Vol. 341, No. 11, Medical Progress.
	9.	M. Mock et al., "Anthrax", 2001, pp. 647-71, Vol. 55, Annu. Rev. Microbiol.
	10.	G. Vitale et al., "Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured Macrophages", 1998, pp. 706-11, Vol. 248, Biochemical and Biophysical Research Communications.
	11.	G. Vitale et al., "Susceptibility of Mitogen-Activated Protein Kinase Kinase Family Members to Proteolysis by Anthrax Lethal Factor", 2000, pp. 739-745, Vol. 352, Biochem. J.
	12.	D. J. Weber et al., "In Vitro Susceptibility of Bacillus spp. to Selected Antimicrobial Agents", 1988, pp. 642-645, Vol. 32, No. 5, Antimicrobial Agents and Chemotherapy.
	13.	E. Helgason et al., "Bacillus Anthracis, Bacillus Cereus, and Bacillus Thuringiensis-One Species on the Basis of Genetic Evidence", 2000, pp. 2627-2630, Vol. 66, No. 6, Applied and Environmental Microbiology.
	14.	N. S. Duesbery et al., "Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor" 1998, pp. 734-737, Vol. 280, Science.
	15.	S. E. Hammond et al., "Lethal Factor Active-Site Mutations Affect Catalytic Activity in Vitro", 1998, pp. 2374-2378, Vol. 66, No. 5, Infection and Immunity.
	16.	R. T. Cummings et al., "Peptide-based fluorescence Resonance Energy Transfer Assay for Bacillus Anthracis Lethal Factor Protease", 2002, pp. 6603-6606, Vol. 99, No. 10, PNAS.
✓	17.	M. Doganay et al., "Antimicrobial Susceptibility of Bacillus Anthracis" 1991, pp. 333-335, Vol. 23, Scand J. Infect Dis.

Examiner Signature

/Susannah Chung/

Date Considered

06/06/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 SEND TO Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB-08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

[illegible]

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2003

AUG 08 2005

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/509,972
Filing Date	October 1, 2004
First Named Inventor	Xiong et al.
Group Art Unit	To be Assigned
Examiner Name	To be Assigned
Attorney Docket Number	21111YP

[illegible][illegible]

**Examiner
Signature**

/Susannah Chung!


Date Considered

06/06/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/509,972
		Filing Date	October 1, 2004
		First Named Inventor	Xiong et al.
		Group Art Unit	To be Assigned
		Examiner Name	To be Assigned
Sheet	3	of	3
		Attorney Docket Number	21111YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/S.C./		A. Scozzafava et al., "Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N-Hydroxysulfonamides Inhibit both These Zinc Enzymes", 2001, pp. 1016, Vol. 44, J. Medicinal Chemistry. Chemical Abstract 137:194969
		S. M. Dankwardt et al., "Amino Acid Derived Sulfonamide Hydroxamates as Inhibitors of Procollagen C-Proteinase: Solid-Phase Synthesis of Ornithine Analogues", 2001, pp. 2085-2088, Vol. 11 (16), Bioorganic & Medicinal Chemistry Letters. Chemical Abstract 135:344719
		S. Pikul et al., "Potent and Selective Carboxylic Acid-Based Inhibitors of Matrix", 2001, pp. 2499-2502, Vol. 44 (16), J. of Medicinal Chemistry. Chemical Abstract 135:210918
		M. Ikeda et al., "Inhibition of Gelatinolytic Activity in Tumor Tissues by Synthetic Matrix Metalloproteinase Inhibitor", 2000, pp. 3290-3296, Vol. 6(8), Clinical Cancer Research. Chemical Abstract 134:125645.
		P. M. O'Brien et al., "Structure-Activity Relationships and Pharmacokinetic Analysis for a Series of Potent, Systemically Available Biphenylsulfonamide Matrix", 2000, pp. 156-166, Vol 43(2), J. of Medicinal Chemistry. Chemical Abstract 132:231496
		V. G. Reddy, "A Novel, Simple and Practical Protocol for N-protected-alpha-amino Hydroxamic Acids", 1999, pp. 3613-3619, Vol. 29 (20), Synthetic Communications. Chemical Abstract 131:286005
		T. Brennan, "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis", 1998, pp. 33-45, Vol. 61(1), Biotechnology and Bioengineering. Chemical Abstract 129:29436
		Y. Tamura et al., "Highly Selective and Orally Active Inhibitors of Type IV Collagenase", 1998, pp. 640-619, Vol. 41(4), J. of Medicinal Chemistry. Chemical Abstract 128:188290.
		J. Hansel et al., "Oxazoline Formation via a Palladium-Catalyzed Cyclization: a Direct, Stereoselective Approach to Cis-5-Amino-2-Cyclopenten-1-ol Derivatives", 1995, pp. 2913-16, Tetrahedron Letters. Chemical Abstract 123:227656.
		S. Natelson et al., "Preparation of D-, DL-, and L-Homoserine Lactone from Methionine", 1989, pp. 226-32, Vol. 40(2), Microchemical J. Chemical Abstract 112:179786.
		N. Yoneda et al., "Reaction of L-alpha-tosylamido-Bet-Propiolactone. I. Synthesis, Reactions with Amines, and Derivation to L-Serine", 1969, pp. 98-103, Vol. 89(1), Yakugaku Zasshi. Chemical Abstract 70:88228
		K. Takahashi et al., "Phenylsulfonamide Derivative", 1998, 10-204059, Patent Abstracts of Japan.
		K. Takahashi et al., "Phenylsulfonamide Derivative", 1997, 11-035557, Patent Abstracts of Japan.
		F. Watanabe et al., "MMP-8 Inhibitor", 1998, 11-246527, Patent Abstracts of Japan.

Examiner Signature	/Susannah Chung/	Date Considered	06/06/2007
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005